March 20th 2024- Prof. Michael Schmitt – Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
By efrat|2024-03-12T14:17:08+00:00March 19th, 2024|All|Comments Off on March 20th 2024- Prof. Michael Schmitt – Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
About the Author: efrat
Related Posts
July 7th 2024- Dr. Anand Patel- Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
July 7th 2024- Dr. Anand Patel- Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
June 24th 2024- Dr. Tamar Tadmor- Supplement of Vitamin D for early-stage Chronic Lymphocytic Leukemia Patients is Associated with a Longer Time to first Treatment